Skip to main content
SpringerLink
Log in

Stem Cell Transplantation in Multiple

  • Chapter
Hematopoietic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

  • 1308 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet 1992;339(8787):200–5.

    PubMed  CAS  Google Scholar 

  2. Group MTC. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 1998;16(12):3832–42.

    Google Scholar 

  3. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxoru-bicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989;2(8668):882–5.

    PubMed  CAS  Google Scholar 

  4. Raje N, Powles R, Kulkarni S, et al. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 1997;97(1):153–60.

    PubMed  CAS  Google Scholar 

  5. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983;2(8354):822–4.

    PubMed  CAS  Google Scholar 

  6. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24(3):431–6.

    PubMed  CAS  Google Scholar 

  7. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenal-idomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106(13):4050–3.

    PubMed  CAS  Google Scholar 

  8. Richardson PG, Schlossman R, Mitsiades C, Hideshima T, Munshi N, Anderson K. Emerging trends in the clinical use of bortezomib in multiple myeloma. Clin Lymphoma Myeloma 2005;6(2):84–8.

    PubMed  Google Scholar 

  9. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129(6):776–83.

    Google Scholar 

  10. Cavo M, Baccarani M. The changing landscape of myeloma therapy. N Engl J Med 2006;354(10):1076–8.

    PubMed  CAS  Google Scholar 

  11. Barlogie B, Tricot G. Complete response in myeloma: a Trojan horse? Blood 2006;108(7):2134.

    CAS  Google Scholar 

  12. Gore ME, Selby PJ, Viner C, et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989;2(8668):879–82.

    PubMed  CAS  Google Scholar 

  13. Attal M, Harousseau JL. Randomized trial experience of the Intergroupe Francophone du Myelome. Semin Hematol 2001;38(3):226–30.

    PubMed  CAS  Google Scholar 

  14. Attal M, Huguet F, Schlaifer D, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992;79(5):1130–6.

    PubMed  CAS  Google Scholar 

  15. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000;95(1):7–11.

    PubMed  CAS  Google Scholar 

  16. Blade J, San Miguel JF, Fontanillas M, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. J Clin Oncol 1996;14(7):2167–73.

    PubMed  CAS  Google Scholar 

  17. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome [see comments]. N Engl J Med 1996;335(2):91–7.

    PubMed  CAS  Google Scholar 

  18. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92(9):3131–6.

    PubMed  CAS  Google Scholar 

  19. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23(36):9227–33.

    PubMed  CAS  Google Scholar 

  20. Facon T, Mary J Y, Harousseau JL, al. e. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM)- preliminary results of a prospective randomized trial (CIAM protocol). Blood 1996;88(s1):685a abstract 2729.

    Google Scholar 

  21. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348(19):1875–83.

    PubMed  CAS  Google Scholar 

  22. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24(6):929–36.

    PubMed  CAS  Google Scholar 

  23. Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005;106(12):3755–9.

    PubMed  CAS  Google Scholar 

  24. Segeren CM, Sonneveld P, van der Holt B, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003;101(6):2144–51.

    PubMed  CAS  Google Scholar 

  25. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104(10):3052–7.

    PubMed  CAS  Google Scholar 

  26. Facon T, Mary J, Harousseau J, et al. Superiority of melphalan-prednisone (MP) + tha-lidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. In: The American Society of Clinical Oncology; 2006; Altanta, Georgia: Journal of Clinical Oncology; 2006. p. 1s.

    Google Scholar 

  27. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autolo-gous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007;13(2):183–96.

    PubMed  CAS  Google Scholar 

  28. Harousseau JL, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma. Stem Cells 1995;13 Suppl 2:132–9.

    PubMed  Google Scholar 

  29. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99(3):731–5.

    PubMed  CAS  Google Scholar 

  30. Owen RG, Johnson RJ, Rawstron AC, et al. Assessment of IgH PCR strategies in multiple myeloma. J Clin Pathol 1996;49(8):672–5.

    PubMed  CAS  Google Scholar 

  31. Corradini P, Voena C, Astolfi M, et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995;85(6):1596–602.

    PubMed  CAS  Google Scholar 

  32. Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol 1997;97(1):46–55.

    PubMed  CAS  Google Scholar 

  33. Johnson RJ, Owen RG, Smith GM, et al. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. Bone Marrow Transplant 1996;17(5):723–7.

    PubMed  CAS  Google Scholar 

  34. Vescio R, Schiller G, Stewart AK, et al. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999;93(6):1858–68.

    PubMed  CAS  Google Scholar 

  35. Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001;19(17):3771–9.

    PubMed  CAS  Google Scholar 

  36. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93(1):51–4.

    PubMed  CAS  Google Scholar 

  37. Qazilbash MH, Saliba RM, Hosing C, et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 2007;39(5):279–83.

    PubMed  CAS  Google Scholar 

  38. Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001;114(4):822–9.

    PubMed  CAS  Google Scholar 

  39. Sirohi B, Powles R, Mehta J, et al. The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients. Med Oncol 2001;18(1):39–50.

    PubMed  CAS  Google Scholar 

  40. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89(3):789–93.

    PubMed  CAS  Google Scholar 

  41. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93(1):55–65.

    PubMed  CAS  Google Scholar 

  42. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349(26):2495–502.

    PubMed  CAS  Google Scholar 

  43. Fermand JP, Alberti C, Marolleau JP. Single versus tandem high dose therapy (HDT) supported with autologous stem cell transplantation using unselected or CD34 enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma. The Hematol J 2003;4 (suppl):559–60.

    Google Scholar 

  44. Cavo M, Zamagni E, Cellini C, al. E. Superiority of double over single autolo-gous stem cell transplantation as first-line rherapy for multiple myeloma. Blood 2004;104:536a.

    Google Scholar 

  45. Goldschmidt H. Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial. Haematologica 2005;90(s1):38.

    Google Scholar 

  46. Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125(1):64–8.

    PubMed  Google Scholar 

  47. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106(8):2837–40.

    PubMed  CAS  Google Scholar 

  48. Avet-Loiseau H, Li J Y, Facon T, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998;58(24):5640–5.

    PubMed  CAS  Google Scholar 

  49. Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005;105(1):358–60.

    PubMed  CAS  Google Scholar 

  50. Fassas AB, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002;118(4):1041–7.

    PubMed  CAS  Google Scholar 

  51. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97(6):1566–71.

    PubMed  CAS  Google Scholar 

  52. Lahuerta JJ, Martinez-Lopez J, Serna JD, et al. Remission status defined by immun-ofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000;109(2):438–46.

    PubMed  CAS  Google Scholar 

  53. Davies FE, Forsyth PD, Rawstron AC, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001;112(3):814–9.

    PubMed  CAS  Google Scholar 

  54. Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100(9):3095–100.

    PubMed  CAS  Google Scholar 

  55. Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999;17(1):208–15.

    PubMed  CAS  Google Scholar 

  56. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000;18(11):2273–81.

    PubMed  CAS  Google Scholar 

  57. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995;13(6):1312–22.

    PubMed  CAS  Google Scholar 

  58. Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001;113(1):209–16.

    PubMed  CAS  Google Scholar 

  59. Bjorkstrand B, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996;88:4711–8.

    PubMed  CAS  Google Scholar 

  60. Bjorkstrand B. European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol 2001;38(3):219–25.

    PubMed  CAS  Google Scholar 

  61. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344(3):175–81.

    PubMed  CAS  Google Scholar 

  62. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001;98(12):3192–204.

    PubMed  CAS  Google Scholar 

  63. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997;90(10):4206–11.

    PubMed  CAS  Google Scholar 

  64. Alyea E, Weller E, Schlossman R, et al. T-cell—depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001;98(4):934–9.

    PubMed  CAS  Google Scholar 

  65. Mehta J, Singhal S. Graft-versus-myeloma. Bone Marrow Transplant 1998;22(9):835–43.

    PubMed  CAS  Google Scholar 

  66. Storb R, Yu C, Sandmaier B, et al. Mixed hematopoietic chimerism after hemat-opoietic stem cell allografts. Transplant Proc 1999;31(1–2):677–8.

    PubMed  CAS  Google Scholar 

  67. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102(9):3447–54.

    PubMed  CAS  Google Scholar 

  68. Lee CK, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003;31(1):73–80.

    PubMed  Google Scholar 

  69. Giralt S, Bensinger W, Goodman M, et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 2003;102(7):2684–91.

    PubMed  CAS  Google Scholar 

  70. Einsele H, Schafer HJ, Hebart H, et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003;121(3):411–8.

    PubMed  Google Scholar 

  71. Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100(3):755–60.

    PubMed  Google Scholar 

  72. Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002;100(12):3919–24.

    PubMed  CAS  Google Scholar 

  73. Galimberti S, Benedetti E, Morabito F, et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res 2005;29(8):961–6.

    PubMed  CAS  Google Scholar 

  74. Peggs KS, Mackinnon S, Williams CD, et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003;9(4):257–65.

    PubMed  Google Scholar 

  75. Mohty M, Boiron JM, Damaj G, et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004;34(1):77–84.

    PubMed  CAS  Google Scholar 

  76. Gerull S, Goerner M, Benner A, et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005;36(11):963–9.

    PubMed  CAS  Google Scholar 

  77. Ma SY, Lie AK, Au WY, Chim CS, Kwong YL, Liang R. Non-myeloablative allo-geneic peripheral stem cell transplantation for multiple myeloma. Hong Kong Med J 2004;10(2):77–83.

    PubMed  CAS  Google Scholar 

  78. Perez-Simon JA, Martino R, Alegre A, et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003;121(1):104–8.

    PubMed  Google Scholar 

  79. Hoepfner S, al. E. Blood 2002;100:859a. Is this a complete reference?

    Google Scholar 

  80. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity alloge-neic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005;105(11):4532–9.

    PubMed  CAS  Google Scholar 

  81. Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002;20(5):1295–303.

    PubMed  Google Scholar 

  82. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107(9):3474–80.

    PubMed  CAS  Google Scholar 

  83. Bruno B, Rotta M, Patriarca F, al. E. Double autologous transplant versus tandem autologus — non myeloablative allogeneic transplant for newly diagnosed multiple myeloma. Blood 2005;106:46.

    Google Scholar 

  84. Moreau P, Hullin C, Garban F, et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 2006;107(1):397–403.

    PubMed  CAS  Google Scholar 

  85. Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002;99(9):3163–8.

    PubMed  CAS  Google Scholar 

  86. Group TMTC. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001;113(4):1020–34.

    Google Scholar 

  87. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108(10):3289–94.

    PubMed  CAS  Google Scholar 

  88. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354(10):1021–30.

    PubMed  CAS  Google Scholar 

  89. Kroger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004;104(10):3361–3.

    PubMed  Google Scholar 

  90. van de Donk NW, Kroger N, Hegenbart U, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006;107(8):3415–6.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Paul G. Richardson for his review and comments on the manuscript.

Author information

Authors and Affiliations

  1. Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA

    John Koreth MBBS, DPhil

  2. Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX

    Kenneth C. Anderson MD

Authors
  1. John Koreth MBBS, DPhil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth C. Anderson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, DFCI D1B30, Boston, MA, 02115, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Koreth, J., Anderson, K.C. (2008). Stem Cell Transplantation in Multiple. In: Soiffer, R.J. (eds) Hematopoietic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-438-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-438-4_8

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-05-3

  • Online ISBN: 978-1-59745-438-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation